Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0360
-0.0030 (-7.69%)
At close: Jul 7, 2026
Adaptimmune Therapeutics Employees
Adaptimmune Therapeutics had 272 employees as of December 31, 2025. The number of employees decreased by 234 or -46.25% compared to the previous year.
Employees
272
Change (1Y)
-234
Growth (1Y)
-46.25%
Revenue / Employee
$21,779
Profits / Employee
$92,669
Market Cap
9.54M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 272 | -234 | -46.25% |
| Dec 31, 2024 | 506 | 57 | 12.69% |
| Dec 31, 2023 | 449 | -85 | -15.92% |
| Dec 31, 2022 | 534 | 40 | 8.10% |
| Dec 31, 2021 | 494 | 32 | 6.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| NKGen Biotech | 26 |
| Zeo ScientifiX | 20 |
| Brainstorm Cell Therapeutics | 19 |
| Reviva Pharmaceuticals Holdings | 14 |
| Inhibitor Therapeutics | 8 |
| Galera Therapeutics | 3 |
| Anebulo Pharmaceuticals | 3 |
| Synlogic | 1 |
Adaptimmune Therapeutics News
- 8 months ago - Adaptimmune Announces Changes to Board and Executive Leadership Team - Newsfile Corp
- 9 months ago - Adaptimmune Announces Delisting from Nasdaq - Newsfile Corp
- 11 months ago - Adaptimmune Reports Q2 Financial Results and Provides Business Update - Newsfile Corp
- 11 months ago - Adaptimmune Therapeutics Quarterly report: Q2 2025 - Filings
- 11 months ago - Adaptimmune Therapeutics Earnings release: Q2 2025 - Filings
- 1 year ago - Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds - Newsfile Corp
- 1 year ago - Adaptimmune Therapeutics Earnings Call Transcript: Q1 2025 - Transcripts
- 1 year ago - Adaptimmune Therapeutics Quarterly report: Q1 2025 - Filings